Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed~* Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic arthritis (CASPAR) criteria~* Active spinal disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) score ≥ 4~* Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)~* Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4 weeks period~Exclusion Criteria:~* History of exposure to other IL-17 or IL-23 inhibitor biologic drug~* History of exposure to previous biologic disease modifying anti-rheumatic drugs (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)~* Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than Methotrexate~* Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician~Other protocol-defined inclusion and exclusion criteria may have applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150mg (Type: EXPERIMENTAL): Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
- AIN457 300mg (Type: EXPERIMENTAL): Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
- AIN457 Placebo (Type: PLACEBO_COMPARATOR): Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).